metaflumizone: an insecticide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 9827529 |
| CHEBI ID | 81803 |
| SCHEMBL ID | 1117478 |
| MeSH ID | M0521041 |
| Synonym |
|---|
| C18523 |
| metaflumizone |
| 139968-49-3 |
| AKOS015909784 |
| CHEBI:81803 |
| SCHEMBL1117478 |
| dtxsid6040373 , |
| tox21_303944 |
| NCGC00357180-01 |
| dtxcid60196514 |
| cas-139968-49-3 |
| hydrazinecarboxamide, 2-(2-(4-cyanophenyl)-1-(3-(trifluoromethyl)phenyl)ethylidene)-n-(4-(trifluoromethoxy)phenyl)-, (2z)- |
| 298TMI336S , |
| unii-298tmi336s |
| 139970-56-2 |
| metaflumizone, (z)- |
| DTXSID90274051 |
| (z)-metaflumizone |
| J-007340 |
| 1-[(z)-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]amino]-3-[4-(trifluoromethoxy)phenyl]urea |
| (2e)-2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-n-[4-(trifluoromethoxy)phenyl]hydrazinecarboxamide; (e)-metaflumizone |
| CS-0065513 |
| hydrazinecarboxamide, 2-[2-(4-cyanophenyl)-1-[3-(trifluoromethyl)phenyl]ethylidene]-n-[4-(trifluoromethoxy)phenyl]- |
| MS-29406 |
| HY-116448 |
| 2'-[2-(4-cyanophenyl)-1-(alpha,alpha,alpha-trifluoro-m-tolyl)ethylidene]-4-(trifluoromethoxy)carbanilohydrazide |
| (e)-metaflumizone 100 microg/ml in acetonitrile |
| metaflumizone (z-isomer) |
| mifommkavscnkq-hwiufgazsa-n |
| metaflumizone 100 microg/ml in acetonitrile |
Metaflumizone is a voltage-dependent sodium channel blocker insecticide, which is chemically similar to indoxacarb. It has been reported to block insect sodium channels in the slow-inactivated state, thereby implying that it is also member of the SCI class.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metaflumizone is a novel semicarbazone insecticide. " | ( Resistance Risk Evaluated by Metaflumizone Selection and the Effects on Toxicities Over Other Insecticides in Spodoptera exigua (Lepidoptera: Noctuidae). Gao, B; Gu, HL; Jiang, YJ; Li, HY; Ma, JJ; Su, J; Sun, XX; Tian, XR; Wang, F; Wang, K; Zhang, JX; Zhou, JC, 2019) | 2.25 |
| "Metaflumizone is a voltage-dependent sodium channel blocker insecticide, which is chemically similar to indoxacarb. " | ( Methemoglobinemia associated with metaflumizone poisoning. Choi, KH; Oh, JS, 2014) | 2.12 |
| "Metaflumizone is a new insecticide for the treatment of fleas on domesticated pets and has recently been reported to block insect sodium channels in the slow-inactivated state, thereby implying that it is also a member of the SCI class." | ( Role of the local anesthetic receptor in the state-dependent inhibition of voltage-gated sodium channels by the insecticide metaflumizone. Soderlund, DM; von Stein, RT, 2012) | 1.31 |
| "Metaflumizone is a novel sodium channel blocker insecticide of semicarbazone class. " | ( Persistence of metaflumizone on cabbage (Brassica oleracea Linne) and soil, and its risk assessment. Chatterjee, NS; Gupta, S, 2013) | 2.19 |
| "Metaflumizone is a new insecticide developed for crop protection and urban pest control by BASF. " | ( Toxicological properties of metaflumizone. Bögi, C; Fabian, E; Fegert, I; Hellwig, J; Hempel, K; Hess, FG, 2007) | 2.08 |
| "Metaflumizone is a novel semicarbazone insecticide, derived chemically from the pyrazoline sodium channel blocker insecticides (SCBIs) discovered at Philips-Duphar in the early 1970s, but with greatly improved mammalian safety. " | ( Metaflumizone is a novel sodium channel blocker insecticide. Hayashi, JH; Salgado, VL, 2007) | 3.23 |
Metaflumizone plus amitraz at the minimum proposed dose rate at monthly (two treatments) or two-weekly (four treatments) intervals resulted in a rapid reduction of mites and improved clinical signs. Treatment provided 99.3% efficacy for 3 weeks, 97.4, 91.4 and 86.2% efficacy at 4, 5 and 6 weeks post-treatment.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Metaflumizone treatment resulted in significantly lower flea numbers relative to non-treated controls on all post-treatment count days (P<0.05)." | ( Efficacy of a novel formulation of metaflumizone for the control of fleas (Ctenocephalides felis) on cats. Carter, L; Dryden, MW; Hair, JA; Holzmer, S; Young, DR, 2007) | 1.34 |
| "Treatment with metaflumizone plus amitraz at the minimum proposed dose rate at monthly (two treatments) or two-weekly (four treatments) intervals resulted in a rapid reduction of mites and improved clinical signs." | ( Efficacy of a novel formulation of metaflumizone plus amitraz for the treatment of sarcoptic mange in dogs. du Plessis, A; Fourie, LJ; Kok, DJ; Rugg, D, 2007) | 0.96 |
| "Treatment with metaflumizone provided > or = 99.3% efficacy for 3 weeks post-treatment and then 97.4, 91.4 and 86.2% efficacy at 4, 5 and 6 weeks post-treatment, respectively." | ( Efficacy of a topically applied spot-on formulation of a novel insecticide, metaflumizone, applied to cats against a flea strain (KS1) with documented reduced susceptibility to various insecticides. Dryden, M; Lowe, A; Mailen, S; Payne, P; Rugg, D; Smith, V, 2008) | 0.92 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " Results from these four studies indicate repeated use of metaflumizone plus amitraz causes no adverse health effects when used as recommended in dogs as young as 8 weeks of age." | ( Safety of a topically applied spot-on formulation of metaflumizone plus amitraz for flea and tick control in dogs. Heaney, K; Lindahl, RG, 2007) | 0.83 |
| " No other adverse signs were observed." | ( Safety of a topically applied metaflumizone spot-on formulation for flea control in cats and kittens. Heaney, K; Lindahl, RG, 2007) | 0.63 |
| Excerpt | Reference | Relevance |
|---|---|---|
| " The frequency of measurable levels of metaflumizone in the plasma was too low to allow the calculation of pharmacokinetic parameters." | ( Pharmacokinetics of metaflumizone in the plasma and hair of cats following topical application. Blond-Riou, F; DeLay, RL; Delprat, S; Lacoste, E, 2007) | 0.93 |
A controlled clinical trial was carried out to assess the effectiveness of pyriprole, metaflumizone combined with amitraz, and fipronil-(S)-methoprene commercial spot-on products.
| Excerpt | Reference | Relevance |
|---|---|---|
| "A controlled clinical trial was performed to assess the effectiveness of a pyriprole (125 mg/ml) and a metaflumizone (150 mg/ml) combined with amitraz (150 mg/ml) spot-on treatment (recommended dosage) in preventing adult female sandflies (Phlebotomus perniciosus) from feeding on dogs." | ( The effectiveness of a pyriprole (125 mg/ml) and a metaflumizone (150 mg/ml) combined with amitraz (150 mg/ml) spot-on treatment in preventing Phlebotomus perniciosus from feeding on dogs. Franc, M; Roques, M; Thomas, C, 2008) | 0.81 |
| "A controlled clinical trial was carried out to assess the effectiveness of pyriprole, metaflumizone combined with amitraz, and fipronil-(S)-methoprene commercial spot-on products in preventing adult female Culex pipiens pipiens from feeding on dogs." | ( Efficacy of fipronil-(S)-methoprene, metaflumizone combined with amitraz, and pyriprole commercial spot-on products in preventing Culex pipiens pipiens from feeding on dogs. Bouhsira, E; Franc, M; Fysikopoulos, A, 2009) | 0.85 |
One hundred eighty one dogs with tick infestation and 170 dogs with flea infestation qualified as primary patients. Four laboratory studies were conducted in Beagle dogs to evaluate the safety of a novel low-volume topical spot-on.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Plasma or hair samples were collected from each cat just prior to dosing and periodically through 56 days after treatment." | ( Pharmacokinetics of metaflumizone in the plasma and hair of cats following topical application. Blond-Riou, F; DeLay, RL; Delprat, S; Lacoste, E, 2007) | 0.66 |
| "Four laboratory studies were conducted in Beagle dogs to evaluate the safety of a novel ectoparasiticide combination of metaflumizone plus amitraz (ProMeris/ProMeris Duo for Dogs, Fort Dodge Animal Health, Overland Park, KS) when applied according to the recommended dosage of >/=20mgmetaflumizonekg(-1) plus >/=20mgamitrazkg(-1), at exaggerated and repeated dosages, and if accidentally orally ingested." | ( Safety of a topically applied spot-on formulation of metaflumizone plus amitraz for flea and tick control in dogs. Heaney, K; Lindahl, RG, 2007) | 0.8 |
| " A total of 173 cats with flea infestation qualified as primary patients and were randomly allocated to one of the two treatments in a ratio of approximately 2:1 for metaflumizone (minimum dosage of 40mg/kg) or fipronil (at the recommended label rate)." | ( Evaluation of the efficacy and safety of a novel formulation of metaflumizone in cats naturally infested with fleas in Europe. Adler, K; DeLay, RL; Hellmann, K; Parker, L; Pfister, K; Rugg, D, 2007) | 0.77 |
| " One hundred eighty one dogs with tick infestation and 170 dogs with flea infestation (plus three dogs harboring both ticks and fleas) qualified as primary patients and were randomly allocated to one of two treatments in a ratio of approximately 2:1 for metaflumizone plus amitraz (minimum dosage of 20 plus 20mg/kg) or fipronil (at the recommended label rate)." | ( Evaluation of the efficacy and safety of a novel formulation of metaflumizone plus amitraz in dogs naturally infested with fleas and ticks in Europe. Adler, K; Delay, RL; Hellmann, K; Parker, L; Pfister, K; Rugg, D, 2007) | 0.76 |
| " Plasma or hair samples were collected from each dog just prior to dosing and periodically through 56 days after treatment." | ( Pharmacokinetics of metaflumizone and amitraz in the plasma and hair of dogs following topical application. Blond-Riou, F; DeLay, RL; Lacoste, E; Mezzasalma, T, 2007) | 0.66 |
| " Therefore, a dosage of 450mLa." | ( Degradation of metaflumizone in rice, water and soil under field conditions. Li, C; Wu, YL; Yang, T, 2012) | 0.73 |
| Class | Description |
|---|---|
| stilbenoid | Any olefinic compound characterised by a 1,2-diphenylethylene backbone. |
| semicarbazone | A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-acylated nitrogen of semicarbazide or its substituted derivatives. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 61.6448 | 3.1890 | 29.8841 | 59.4836 | AID1224846 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 19.3312 | 0.0007 | 14.5928 | 83.7951 | AID1259369 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 35.7471 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
| progesterone receptor | Homo sapiens (human) | Potency | 27.3060 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 27.3060 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 54.9410 | 0.0008 | 17.5051 | 59.3239 | AID1159527 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 15.9983 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224848; AID1224849; AID1259401; AID1259403 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 54.4827 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 24.5412 | 0.0578 | 21.1097 | 61.2679 | AID1159526 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (47.06) | 29.6817 |
| 2010's | 20 (39.22) | 24.3611 |
| 2020's | 7 (13.73) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.92) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 15 (28.85%) | 5.53% |
| Reviews | 2 (3.85%) | 6.00% |
| Case Studies | 1 (1.92%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 34 (65.38%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||